Recruiting

Testing two medications together for rare head and neck cancers

Plain-English translation of NCT07662681 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a combination of two drugs—camrelizumab and famitinib—given together to treat rare and advanced cancers of the head and neck region. These cancers include soft tissue sarcomas, melanoma, adenoid cystic carcinoma, and certain salivary gland tumors. The study will enroll 40 patients and track how well this medication combination works and how safe it is.

Many people with rare, advanced head and neck cancers have limited treatment options, especially if surgery isn't possible. This trial exists to see if combining these two medications—which work in different ways to fight cancer—might offer a new, more effective option for patients who haven't tried certain immunotherapy drugs before.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with advanced, unresectable, recurrent, or metastatic soft tissue sarcoma, melanoma, adenoid cystic carcinoma, or salivary gland cancer (with certain characteristics confirmed by testing)
you have not previously received PD-1 inhibitor therapy
you have received no more than one prior systemic therapy regimen for your cancer
you are in good overall health with adequate organ function (blood counts, kidney and liver function) based on lab tests
you have at least one measurable tumor lesion on imaging

You likely don't qualify if…

you have received radiation or other local therapy within 2 weeks before enrollment
you have significant heart disease or cardiac symptoms, including heart failure, unstable angina, or a recent heart attack
you have high blood pressure that cannot be controlled with medication
you have difficulty swallowing, severe nausea and vomiting, or chronic diarrhea that would prevent you from taking oral medication
you are pregnant, breastfeeding, or unwilling to use effective contraception during and for 6 months after the study

What participation looks like

You will attend a screening visit within 4 weeks before starting treatment to confirm you are eligible. Once enrolled, you will receive camrelizumab as an intravenous injection every 3 weeks and take famitinib as a daily oral tablet, with each 21-day period counting as one treatment cycle. You will have regular visits to the study center for check-ups, blood tests, and imaging scans to monitor how your cancer is responding and any side effects. After you stop treatment, you will have safety follow-up visits at 30, 60, and 90 days, with the later visits conducted by phone, and then survival check-ins every 3 months.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(1 site)

China

the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality

Key details

Phase

Safety & dosing / Early efficacy

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Enrollment target

~40 participants

Started

July 2026

Primary completion

July 2028

Age range

18 Years and older

Last updated on clinicaltrials.gov in June 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Guoxin Ren, M.D.

the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov